PeptideDB

Uridine triacetate

CAS: 4105-38-8 F: C15H18N2O9 W: 370.31

Uridine triacetate (Tri-O-acetyl uridine) is an orally active prodrug of Uridine (HY-B1449). Uridine triacetate is quick
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Uridine triacetate (Tri-O-acetyl uridine) is an orally active prodrug of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS)[1][2].
Invitro Uridine triacetate inhibits [3H]uridine uptake in ENT1 and ENT2 overexpressed HeLa cells, with IC50s of 28.4 μM and 228.4 μM respectively[4].
In Vivo Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced toxicity in 5-FU overdose mice[3].Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced 5-FU toxicity in DPD deficiency mice[3]. Animal Model:
Name Uridine triacetate
CAS 4105-38-8
Formula C15H18N2O9
Molar Mass 370.31
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Ma WW, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017 Jan 1;123(2):345-356. [2]. Cada DJ, et al. Uridine Triacetate. Hosp Pharm. 2016 Jun;51(6):484-8. [3]. Rolando A G Garcia, et al. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. Toxicol Appl Pharmacol. 2018 Aug 15;353:67-73. [4]. Siennah R Miller, et al. Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling. Mol Pharmacol. 2021 Feb;99(2):147-162.